2021 Fiscal Year Final Research Report
Development of a new adoptive immunotherapy using NK cells for pediatric malignant solid tumors
| Project/Area Number |
20K17599
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 55010:General surgery and pediatric surgery-related
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2022-03-31
|
| Keywords | 神経芽腫 / 高活性NK細胞 / 小児悪性固形腫瘍 / 肝芽腫 / 横紋筋肉腫 |
|---|
| Outline of Final Research Achievements |
Natural Killer(NK) cell activated by Adoptcell-NK showed remarkable cytotoxic activity against neuroblastoma (IMR-32), osteosarcoma (HS-OS-1), hepatoblastoma (huh6), rhabdomyosarcoma (RH30) cell line. We confirmed the phenomenon that activated NK cells invade the sphere of the tumor under 3D culture, attack the tumor cells, and destroy the sphere. In particular, IMR-32 and HS-OS-1 have high infiltration efficiency into the sphere and are expected to be clinically applied. In addition, in vivo experiments confirmed the antitumor effect of highly active NK cells in neuroblastoma xenograft model mice.
|
| Free Research Field |
小児外科学分野
|
| Academic Significance and Societal Importance of the Research Achievements |
高活性NK細胞を用いることで小児固形悪性腫瘍に対する細胞障害活性を広く確認することができた。この高活性NK細胞製剤は既に非臨床試験が終了しており、製剤化に成功しているため、今回の前臨床試験の結果を持って小児固形悪性腫瘍を対象としたNK細胞を用いた新規免疫治療の治験を開始する予定である。
|
